Clinical and biomarker changes of Alzheimer&apos;s disease in adults with Down syndrome: a cross-sectional study

Aging and Cognitive FunctionsAlzheimer’s Disease

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease

Neurology.

McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ, Dominantly Inherited Alzheimer Network

doi: 10.1212/

Dementia

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study

Lancet Neurol.

Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR Jr, Hornbeck RC, Paumier KL, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal JP, Correia S, Förster S, Fox NC, Graff-Radford NR, la Fougère C, Levin J, Masters CL, Rossor MN, Salloway S, Saykin AJ, Schofield PR, Thompson PM, Weiner MM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS

doi: 10.1016/

Further Publications NeurologyFurther Publications Psychiatry

Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis

Lancet Neurol.

Scahill RI, Zeun P, Osborne-Crowley K, Johnson EB, Gregory S, Parker C, Lowe J, Nair A, O'Callaghan C, Langley C, Papoutsi M, McColgan P, Estevez-Fraga C, Fayer K, Wellington H, Rodrigues FB, Byrne LM, Heselgrave A, Hyare H, Sampaio C, Zetterberg H, Zhang H, Wild EJ, Rees G, Robbins TW, Sahakian BJ, Langbehn D, Tabrizi SJ

doi: 10.1016/S1474-4422(20)30143-5.

Alzheimer’s Disease

Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study

Lancet Neurol.

Quiroz YT, Zetterberg H, Reiman EM, Chen Y, Su Y, Fox-Fuller JT, Garcia G, Villegas A, Sepulveda-Falla D, Villada M, Arboleda-Velasquez JF, Guzmán-Vélez E, Vila-Castelar C, Gordon BA, Schultz SA, Protas HD, Ghisays V, Giraldo M, Tirado V, Baena A, Munoz C, Rios-Romenets S, Tariot PN, Blennow K, Lopera F

doi: 10.1016/S1474-4422(20)30137-X.

Alzheimer’s Disease

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

Lancet Neurol.

Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J, Schöll M, Massarweh G, Soucy JP, Höglund K, Brinkmalm G, Mattsson N, Palmqvist S, Gauthier S, Stomrud E, Zetterberg H, Hansson O, Rosa-Neto P, Blennow K

doi: 10.

Impact of home visit capacity on genetic association studies of late-onset Alzheimer's disease

Alzheimers Dement.

Fardo DW, Gibbons LE, Mukherjee S, Glymour MM, McCormick W, McCurry SM, Bowen JD, Larson EB, Crane PK

doi: 10.1016/j.jalz.2017.01.012.

Aging and Cognitive FunctionsAlzheimer’s Disease

Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology

JAMA Neurol.

Schreiber S, Schreiber F, Lockhart SN, Horng A, Bejanin A, Landau SM, Jagust WJ; Alzheimer’s Disease Neuroimaging Initiative

doi: 10.1001/jamaneurol.

Dementia

Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia

Alzheimers Dement.

Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, Dardiotis E, Guillo-Benarous F, Hampel H, Kochan NA, Lista S, Luck T, Maruff P, Molinuevo JL, Kornhuber J, Reisberg B, Riedel-Heller SG, Risacher SL, Roehr S, Sachdev PS, Scarmeas N, Scheltens P, Shulman MB, Saykin AJ, Verfaillie SCJ, Visser PJ, Vos SJB, Wagner M, Wolfsgruber S, Jessen F; Alzheimer's Disease Neuroimaging Initiative, the DESCRIPA working group, the INSIGHT-preAD study group, on behalf of the SCD-I working group, van der Flier WM

doi: 10.1016/j.jalz.2018.10.003.

Aging and Cognitive FunctionsDementia

Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome

Eur J Pharmacol.

Caraci F, Iulita MF, Pentz R, Flores Aguilar L, Orciani C, Barone C, Romano C, Drago F, Cuello AC

doi: 10.1016/

Neurology · Psychiatry

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

Related content

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study

Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis

Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

Impact of home visit capacity on genetic association studies of late-onset Alzheimer's disease

Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology

Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia

Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome